On Dec. 3, 2013, Juno Theraputics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, was launched by the Fred Hutchinson Cancer Research Center and Memorial Sloan-Kettering Cancer Center, along with pediatric partner Seattle Children’s Research Institute.

Juno was established with an initial investment of $120 million, making it one of the largest Series A biotech startups in history. Initial investors include leading technology venture capital firm ARCH Venture Partners, Amazon.com founder Jeff Bezos, and the Alaska Permanent Fund. Hans Bishop, a longtime biotech industry veteran, was made company CEO.